Synergistic role of Cul1 and c-Myc: Prognostic and predictive biomarkers in colorectal cancer

Wang,Weimin; Deng,Jianliang; Wang,Qianqian; Yao,Qiang; Chen,Wenjiao; Tan,Yongfei; Ge,Zhijun; Zhou,Jianwei; Zhou,Yan

doi:10.3892/or.2017.5671

Synergistic role of Cul1 and c-Myc: Prognostic and predictive biomarkers in colorectal cancer

Authors:
- Weimin Wang
- Jianliang Deng
- Qianqian Wang
- Qiang Yao
- Wenjiao Chen
- Yongfei Tan
- Zhijun Ge
- Jianwei Zhou
- Yan Zhou
View Affiliations

Affiliations: Department of Oncology, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu 214200, P.R. China, Department of Molecular Cell Biology and Toxicology, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: May 25, 2017 https://doi.org/10.3892/or.2017.5671
Pages: 245-252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumors, and its high rates of recurrence and metastasis are the important causes of treatment failure in CRC. Therefore, the development of valuable molecular markers to accurately predict the prognosis of CRC patients is vital. In the present study, we determined the expression of Cullin1 (Cul1) and c-Myc in a CRC tissue microarray containing 470 cancer and corresponding normal tissues by immunohistochemistry. We found that Cul1 and c-Myc expression was significantly upregulated in the CRC cancer tissues compared with that noted in the adjacent non-cancer tissues. High Cul1 expression in cancer tissues was associated with depth of invasion (P=0.005), lymph node metastasis (P=0.001) and TNM stage (P=0.015). High c-Myc expression in cancer tissues was significantly positively association with age (P=0.004), depth of invasion (P<0.001), lymph node metastasis (P<0.001) and TNM stage (P<0.001). Multivariate Cox regression analysis revealed that Cul1 or c-Myc expression was an independent and unfavorable prognostic factor for CRC patients [hazard ratio (HR), 0.749, 95% confidence interval (CI), 0.563-0.996, P<0.05; and HR, 0.384, 95% CI, 0.257-0.472, P<0.001, respectively]. Furthermore, Cul1 and c-Myc exhibited synergistic potential for the prediction of CRC prognosis, and the patients with low expression of both Cul1 and c-Myc had a favorable survival outcome (P<0.001).

View Figures

View References

1	Wan DS: Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng. 28:897–902. 2009.(In Chinese). PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar : PubMed/NCBI
4	Paul S: Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: Therapeutic approaches. BioEssays. 30:1172–1184. 2008. View Article : Google Scholar : PubMed/NCBI
5	Nakayama KI and Nakayama K: Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol. 16:323–333. 2005. View Article : Google Scholar : PubMed/NCBI
6	Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S and Eymin B: Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: Relationships with CAND1 and cyclin E protein levels. J Pathol. 213:303–310. 2007. View Article : Google Scholar : PubMed/NCBI
7	Chen BB, Glasser JR, Coon TA and Mallampalli RK: F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene. 31:2566–2579. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chen BB, Glasser JR, Coon TA, Zou C, Miller HL, Fenton M, McDyer JF, Boyiadzis M and Mallampalli RK: F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood. 119:3132–3141. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wang W, Chen Y, Deng J, Zhou J, Gu X, Tang Y, Zhang G, Tan Y, Ge Z, Huang Y, et al: Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer. J Cancer Res Clin Oncol. 141:1603–1612. 2015. View Article : Google Scholar : PubMed/NCBI
10	Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, Zhou J and Li G: Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 42:375–383. 2011. View Article : Google Scholar : PubMed/NCBI
11	Chen G and Li G: Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol. 37:1339–1344. 2010.PubMed/NCBI
12	Chen G, Cheng Y, Martinka M and Li G: Cul1 expression is increased in early stages of human melanoma. Pigment Cell Melanoma Res. 23:572–574. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP and Zheng JN: Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol. 24:2016–2022. 2013. View Article : Google Scholar : PubMed/NCBI
14	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
15	van Riggelen J, Yetil A and Felsher DW: MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 10:301–309. 2010. View Article : Google Scholar : PubMed/NCBI
16	Meyer KD, Donner AJ, Knuesel MT, York AG, Espinosa JM and Taatjes DJ: Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. EMBO J. 27:1447–1457. 2008.PubMed/NCBI
17	Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A and Haglund C: CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 13:289–295. 2012. View Article : Google Scholar : PubMed/NCBI
18	O'Hagan RC, Ohh M, David G, De Alboran IM, Alt FW, Kaelin WG Jr and DePinho RA: Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 14:2185–2191. 2000. View Article : Google Scholar : PubMed/NCBI
19	Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J, et al: Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 18:2987–2996. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yang X, Takano Y and Zheng HC: The pathobiological features of gastrointestinal cancers (Review). Oncol Lett. 3:961–969. 2012.PubMed/NCBI
21	Xu M, Yang X, Zhao J, Zhang J, Zhang S, Huang H, Liu Y and Liu J: High expression of Cullin1 indicates poor prognosis for NSCLC patients. Pathol Res Pract. 210:397–401. 2014. View Article : Google Scholar : PubMed/NCBI
22	Hatakeyama S, Watanabe M, Fujii Y and Nakayama KI: Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res. 65:7874–7879. 2005.PubMed/NCBI
23	Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, Martinez SA, Chen EY, Lee C and Langenau DM: Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell. 25:366–378. 2014. View Article : Google Scholar : PubMed/NCBI
24	Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB, Choe G, Kim WH and Lee HS: c-MYC copy-number gain is an independent prognostic factor in patients with colorectal cancer. PLoS One. 10:e01397272015. View Article : Google Scholar : PubMed/NCBI
25	Khaleghian M, Shakoori A, Razavi AE and Azimi C: Relationship of amplification and expression of the C-MYC gene with survival among gastric cancer patients. Asian Pac J Cancer Prev. 16:7061–7069. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zeng W, Sun H, Meng F and Liu Z, Xiong J, Zhou S, Li F, Hu J, Hu Z and Liu Z: Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int J Clin Exp Pathol. 8:1878–1888. 2015.PubMed/NCBI
27	Huang W, Guo L, Liu H, Zheng B, Ying J and Lv N: C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. Int J Clin Exp Pathol. 7:5634–5644. 2014.PubMed/NCBI
28	Zhang Y, Li J, Xi Y, Bai W, Bai W and Sun R: Significance of C-myc expression in T-lymphoblastic lymphoma/leukemia and its relation with prognosis. Zhonghua Bing Li Xue Za Zhi. 44:571–577. 2015.PubMed/NCBI
29	Seo AN, Yang JM, Kim H, Jheon S, Kim K, Lee CT, Jin Y, Yun S, Chung JH and Paik JH: Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 110:2688–2699. 2014. View Article : Google Scholar : PubMed/NCBI
30	Deming SL, Nass SJ, Dickson RB and Trock BJ: C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 83:1688–1695. 2000. View Article : Google Scholar : PubMed/NCBI
31	Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, et al: CDK-mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 5:1067–1086. 2013. View Article : Google Scholar : PubMed/NCBI